US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort

    Hørsholm, Denmark, 19 December 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports (i) updated immunogenicity results from the first three patients enrolled in its ongoing Phase I clinical trial of ES2B-C001, a novel HER2-targeted therapeutic breast cancer vaccine, and (ii) that the independent Data Safety Monitoring Board (DSMB) has reviewed safety data from the first cohort and recommended progression to the

    ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial

    Hørsholm, Denmark, 4 September 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer today reports the first immunogenicity results from its ongoing Phase I clinical trial evaluating ES2B-C001, a novel HER2-targeted therapeutic breast cancer vaccine. The data, derived from the first patient enrolled in the trial, indicate that the vaccine is triggering a significant immune response.Early Evidence of Immune Activation The

    Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy

    Hørsholm, Denmark, 30 June 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, “ExpreS2ion” or the “Company”), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates for infectious diseases and cancer, today announced that the Austrian regulatory authorities have approved the Company’s protocol amendment to evaluate its breast cancer immunotherapy candidate, ES2B-C001, in combination with HER2-targeted antibody-drug conjugates (ADCs) and to expand the number of trial sites.Filed on 13 May 2025 

    ExpreS2ion announces a rights issue of units of approximately SEK 60 million

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. INSIDE INFORMATION: Hørsholm, Denmark, 2 May 2024 – The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, subject to

    ExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine

    Hørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces that AdaptVac ApS (“AdaptVac”) has received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s articles of association, has agreed to resolve on the pay-out of excess capital in AdaptVac to the shareholders of AdaptVac, which are ExpreS2ion (34% share ownership) and NextGen Vaccines Holding ApS (“NextGen”)

    ExpreS2ion further strengthens leadership team with appointment of Chief Scientific Officer

    Hørsholm, Denmark, January 3, 2023 – ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion” or the “Company”) hereby announces the appointment of Dr. Farshad Guirakhoo as the Company’s new Chief Scientific Officer (CSO). Dr. Guirakhoo has more than 30 years of broad translational research experience in the vaccine development field, and will be responsible for directing the development of the discovery and preclinical strategies and plans that support ExpreS[2]ion’s development pipeline of unique vaccine assets, including managing the progression of ExpreS[2]ion’s vaccine technology platform. Dr.

    ExpreS2ion Announces Formation of Oncology Scientific Advisory Board

    Hørsholm, Denmark, November 3, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development of ExpreS2ion’s proprietary HER2-cVLP breast cancer vaccine, ES2B-C001. The OSAB will serve as advisors, potential contributors to the planned clinical studies and participants in Key Opinion Leader

    Additional positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

    Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated additional positive proof-of-concept also in a metastatic outgrowth therapeutic tumor mice model. These data support the already established preclinical proof-of-concept results announced in December 2021 

    ExpreS2ion provides an update on its novel breast cancer vaccine candidate ES2B-C001

    Hørsholm, Denmark, February 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) announces constructive feedback from its scientific advice meeting pertaining to the therapeutic breast cancer vaccine candidate, ES2B-C001, with the Danish Medicines Agency (“DKMA”). Based on this feedback, ExpreS2ion plans to conduct an additional preclinical safety study in the first half of 2023, which will increase the robustness of the project’s preclinical data. Consequently, the Company is now aiming to file the clinical trial application for

    ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

    Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important headline results as the therapeutic vaccine is being developed towards first in human clinical investigations in 2023.The additional topline preclinical results

    ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept

    Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively inhibit tumor growth in human cancer cells. The therapeutic vaccine is being developed towards first in human clinical trials in 2023.The topline preclinical

    ExpreS2ion publishes video from company presentation at a Nordic investor event

    ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the LifeSci Advisors Nordic Biotech Summit investor event on June 29, 2021 is now available on the company’s Vimeo channel.The presentation provides an update on ExpreS[2]ion’s development pipeline covering COVID-19, breast cancer, influenza and multiple malaria projects, including an outlook for upcoming activities in 2021-2023. The presentation can be found here: https://vimeo.com/572043181 Certified Adviser Svensk

    Lead candidate selected in ExpreS2ion’s HER2-cVLP breast cancer vaccine project

    Hørsholm, Denmark, May 11, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.ExpreS[2]ion, with the expert assistance of Prof. Pier Luigi Lollini at the Interdepartmental Center for Cancer Research, University of Bologna, has started the preclinical program, exploiting state-of-the-art in vitro and in vivo models mimicking some of the mechanisms in human breast cancer. As part of the preclinical program, ExpreS[2]ion has selected

    ExpreS2ion updates on its pipeline outlook, including for COVID-19 and HER2 breast cancer projects

    Hørsholm, Denmark, March 16, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today presents an updated outlook for its pipeline development projects, including the ABNCoV2 COVID-19 vaccine and its ES2B-C001 HER2-cVLP breast cancer vaccine. The update is published ahead of a digital company presentation to be held today at 11.00 CET, during which CEO Bent U. Frandsen will discuss the promising outlook of ExpreS2ion’s project pipeline in more detail.CEO Bent U. Frandsen comments “We have already seen great progress for ExpreS[2]ion in 2021,

    ExpreS2ion will participate at key industry and investor events in March 2021

    ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna’s Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer

    ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

    Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the recently presented in-licensing of the HER2-cVLP technology from AdaptVac. The outcome of the collaboration is expected to support ExpreS2ion’s breast cancer

    ExpreS2ion granted exclusive global license for HER2-cVLP breast cancer vaccine programme from AdaptVac

    Hørsholm, Denmark, February 2, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the company has today exercised its option to license a unique breast cancer vaccine by signing a final Patent License Agreement (“the Agreement”) with AdaptVac ApS (“AdaptVac”). ExpreS2ion is granted an exclusive global license to a preclinical-stage novel HER2-cVLP breast cancer vaccine programme. Supported by the proceeds from the recent right issue, ExpreS2ion plans to develop the first vaccine candidate, that will be designated ES2B-C001, to human

    Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

    Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS[2]ion’s planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture

    ExpreS2ion publishes video from company presentation at a Danish investor event

    ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at a Danish investor event on October 21, 2020 has been published on the company’s website.This and other recent company presentations can be found on the presentation page of ExpreS[2]ion’s website . CEO Bent U. Frandsen will also hold a presentation at the upcoming Biostock Life Science Summit  event that will take place virtually from Lund and

    ExpreS2ion’s rights issue oversubscribed

    THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW. Hørsholm, Denmark, October 23, 2020 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) has completed the rights issue of shares and  warrants (“Units”)

    ExpreS2ion publishes prospectus in connection with capital raise of up to SEK 216 million

    THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW. Hørsholm, Denmark, September 29, 2020 – the Extraordinary General Meeting (“EGM”) of ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) resolved on

    ExpreS2ion rearranges its event schedule due to Coronavirus restrictions

    ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is rearranging its recently communicated event schedule due to events changes as a results of COVID-19-related travel restrictions. The company’s main priority during this time is to progress rapidly with the ongoing EU Horizon 2020-funded COVID-19 vaccine development project together with the rest of the consortium members.ExpreS[2]ion’s CEO Bent U. Frandsen will present the company for the Aktiedagen event on March 16 in Stockholm virtually, which means you can view it later today at ExpreS[2]ion’s

    ExpreS2ion’s joint venture AdaptVac receives grants for two new projects: cardiovascular disease and breast cancer in dogs

    ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical studies for the ongoing HER2+ human breast cancer vaccine project AV001.The two grants, DKK 1 million for the cardiovascular disease vaccine project and DKK 1.2 million for the AV001 HER2+ breast cancer project, will cover two

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media